About this trial
The study plans to learn more about what happens to the body after bariatric surgery in people 12 to 24 years old. The study aims to understand why people respond differently to bariatric surgery and how to define success beyond weight loss alone. The study also plans to learn more about whether a medication (semaglutide) can help people 12 to 24 years old who, between 1 and 2 years after bariatric surgery, have not lost as much weight as expected.
Eligibility criteria
Qualifiers
Signed and dated informed consent form
Willingness to comply with all study procedures and availability for the duration of the study
Male or female biological sex, age 12 through 24 years
In the preoperative pathway for vertical sleeve gastrectomy
Disqualifiers
Planned Roux-en-Y gastric bypass
Hypothalamic obesity
Type 2 Diabetes
Current use of oral glucocorticoids (i.e. within 10 days of baseline visit)
Trial design
Treatments tested in this trial
- Injectable semaglutide
- Standard postoperative care
Treatment groups
Sponsors and collaborators
University of Colorado, Denver
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator